UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life

Journal of patient-reported outcomes, 2022-05, Vol.6 (1), p.49-49, Article 49

2022

Volltextzugriff (PDF)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam

Open forum infectious diseases, 2023-05, Vol.10 (5), p.ofad173-ofad173

2023

Volltextzugriff (PDF)

Efficacy, Tolerability and Persistence of Subcutaneous Immunoglobulin Provided Through Immunology Physician Practices for the Treatment of Primary Immunodeficiencies

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB115-AB115

2019

Volltextzugriff (PDF)

Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of Its role in apoptosis

Cancer biology & therapy, 2006-05, Vol.5 (5), p.518-522

2006

Volltextzugriff (PDF)

Therapeutic Drug Monitoring of Biologics in Patients With Inflammatory Bowel Disease: A Real World Experience: 740

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S416-S417

2018

Volltextzugriff (PDF)

Real World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease: 703

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S396-S396

2018

Volltextzugriff (PDF)

Healthcare Resource Utilization in Inflammatory Bowel Disease Patients: A 2-Year Analysis: 614

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S351-S351

2018

Volltextzugriff (PDF)

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2685-2695

2006

Volltextzugriff (PDF)

Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers

Anaerobe, 2022-10, Vol.77, p.102617-102617, Article 102617

2022

Volltextzugriff (PDF)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

Open forum infectious diseases, 2020-04, Vol.7 (4), p.ofaa097-ofaa097

2020

Volltextzugriff (PDF)

Outpatient treatment of osteomyelitis with telavancin

International journal of antimicrobial agents, 2017-07, Vol.50 (1), p.93-96

2017

Volltextzugriff (PDF)

Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib

Cancer biology & therapy, 2004-09, Vol.3 (9), p.847-852

2004

Volltextzugriff (PDF)

Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations

Cancer biology & therapy, 2005-04, Vol.4 (4), p.413-419

2005

Volltextzugriff (PDF)

Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines

Journal of experimental therapeutics & oncology, 2007, Vol.6 (3), p.183

2007

Volltextzugriff (PDF)

Involvement of mitochondrial and akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells

Cancer research (Chicago, Ill.), 2006-10, Vol.66 (19), p.9762-9770

2006

Volltextzugriff (PDF)

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Sa1091 – Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimens

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-267-S-267

2019

Volltextzugriff (PDF)

Can Vedolizumab Non-Responders Be Treated Successfully With Another Biologic Agent?: 723

The American journal of gastroenterology, 2017-10, Vol.112, p.S398-S399

2017

Volltextzugriff (PDF)

Long-term Safety Analysis of Vedolizumab for Treatment of Crohnʼs Disease and Ulcerative Colitis: 724

The American journal of gastroenterology, 2017-10, Vol.112, p.S399-S400

2017

Volltextzugriff (PDF)

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Successful Treatment of Inflammatory Bowel Disease with Infliximab in Physician Office Infusion Centers: 2456

The American journal of gastroenterology, 2016-10, Vol.111, p.S1253

2016

Volltextzugriff (PDF)

Tu1887 - Real World Experience of Bezlotoxumab for Prevention of Recurrent C. Difficile Infection: A Single-Arm Multicenter Pilot Study in office Infusion Centers

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1048-S-1048

2018

Volltextzugriff (PDF)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S805-S805

2020

Volltextzugriff (PDF)

1006. High Adherence and Cost Savings with Home OPAT Provided through Infectious Disease Physician Office Infusion Centers

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S704-S705

2018

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam

Efficacy, Tolerability and Persistence of Subcutaneous Immunoglobulin Provided Through Immunology Physician Practices for the Treatment of Primary Immunodeficiencies

Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of Its role in apoptosis

Therapeutic Drug Monitoring of Biologics in Patients With Inflammatory Bowel Disease: A Real World Experience: 740

Real World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease: 703

Healthcare Resource Utilization in Inflammatory Bowel Disease Patients: A 2-Year Analysis: 614

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition

Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

Outpatient treatment of osteomyelitis with telavancin

Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib

Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations

Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines

Involvement of mitochondrial and akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)

Sa1091 – Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimens

Can Vedolizumab Non-Responders Be Treated Successfully With Another Biologic Agent?: 723

Long-term Safety Analysis of Vedolizumab for Treatment of Crohnʼs Disease and Ulcerative Colitis: 724

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software

Successful Treatment of Inflammatory Bowel Disease with Infliximab in Physician Office Infusion Centers: 2456

Tu1887 - Real World Experience of Bezlotoxumab for Prevention of Recurrent C. Difficile Infection: A Single-Arm Multicenter Pilot Study in office Infusion Centers

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)

1006. High Adherence and Cost Savings with Home OPAT Provided through Infectious Disease Physician Office Infusion Centers

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)

Suchergebnisse filtern